Results: Of the 354,930 transplants performed in the United States, adverse reactions were reported in 494 cases (0.139%). Primary graft failure (PGF) predominated (n = 319; 0.09%) followed by endophthalmitis (n = 99; 0.028%) and keratitis (n = 66; 0.019%). The procedure type predominantly associated with PGF was endothelial keratoplasty (EK) in 56% (n = 180; 11 per 10,000 grafts), followed by penetrating keratoplasty (PK) in 42% (n = 135; 6.9 per 10,000 grafts). The procedure type predominantly associated with endophthalmitis and keratitis was EK in 63% (n = 104; 6.3 per 10,000 grafts) followed by PK in 34% (n = 56; 2.8 per 10,000 grafts), anterior lamellar keratoplasty in 1% (n = 2; 2.7 per 10,000 grafts), and keratoprosthesis in 1% (n = 2; 12.4 per 10,000 grafts). Although the incidence of PGF and endophthalmitis between PK and EK was noteworthy, the difference was not statistically significant (P = 0.098). Endophthalmitis-associated pathogens were isolated in 78% of cases: predominantly Candida species (65%), gram-positive organisms (33%), and gram-negative rods (2%). Keratitis-associated pathogens were isolated in 64% of cases: predominantly Candida species (81%), Herpes simplex virus (7%), gram-negative organisms (7%), and grampositive organisms (5%).
T he Eye Bank Association of America (EBAA) monitors adverse reactions of corneal transplants that are potentially attributable to donor eye tissue, including infection and biologic dysfunction. The EBAA initiated an adverse reaction reporting system in 1990 and has used the Online Adverse Reaction Reporting System (OARRS) for reporting since 2004. EBAA Medical Standard M1.500 requires each distributing establishment to seek postoperative outcome information from the surgeon 3 to 6 months after transplant.
Adverse reaction information is forwarded to the source eye bank and submitted to the EBAA within 30 days of the first report. The eye bank tracks the mated donor cornea and reviews donor and recipient records and microbiological results of preimplant donor cultures and recipient cultures. The medical director of the source eye bank establishes imputability or determines the likelihood that the adverse reaction in the recipient can be attributed to the tissue.
A literature search regarding adverse reactions after corneal transplantation, revealed several publications reporting the incidence of post-penetrating keratoplasty of primary graft failure (PGF) [1] [2] [3] [4] and endophthalmitis. [5] [6] [7] [8] [9] [10] There was relative paucity of data reporting: (1) the incidence relative to the procedure type, comparing penetrating keratoplasty (PK), endothelial keratoplasty (EK), anterior lamellar keratoplasty (ALK), and keratoprosthesis (KPro); (2) the incidence of "other" adverse reactions, including infectious keratitis, inadvertent use of postrefractive surgery tissue, transmission of corneal dystrophy, and systemic infection; (3) the changing milieu of infectious pathogens associated with EK compared with PK.
Herein, our analysis of adverse reactions reported to the EBAA represents the efforts of the eye banking and transplant surgeon community to ensure safe and efficacious donor corneal tissue, in addition to monitoring trends and practice patterns.
METHODS
A retrospective review was performed of all adverse reactions reported to the EBAA through OARRS, for corneal transplants performed between January 1, 2007, and December 31, 2014. Data regarding the total number of corneal tissues distributed by U.S. eye banks were obtained from the EBAA Statistical Report from 2014. 11 Adverse reactions were categorized and defined as follows:
• PGF is a edematous graft present from the time of keratoplasty that does not clear after 8 weeks without an identifiable operative or postoperative complication or underlying recipient condition that would explain the biologic dysfunction. • A graft-transmitted ocular infection caused by bacterial, fungal, viral, or Acanthamoeba etiologies and including infectious keratitis and endophthalmitis. • Any systemic infection caused by a relevant communicable disease, such as human immunodeficiency virus (HIV), viral hepatitis, or Creutzfeldt-Jakob disease (CJD), that develops in a recipient, irrespective of whether it is suspected to be because of the donor tissue. The U.S. Food and Drug Administration defines "relevant" as a means of identifying disease transmission risk associated with certain human cell and tissue products. 12 • Transmission of corneal dystrophy, degeneration, or ocular malignancy. • Evidence of prior refractive surgery in the donor tissue inadvertently used during keratoplasty.
Data were summarized using descriptive statistics (median for time to onset and count and frequency for adverse reactions). Yearly and seasonal variations in incidence of adverse reactions were compared among different procedure types using x 2 or Fisher exact test. Median time to onset between different fungal and bacterial infections was compared using Mann-Whitney test. All analyses were performed using SAS 9.4 (SAS Inc, Cary, NC) and a P-value ,0.05 was deemed statistically significant.
RESULTS
When calculating incidence, we chose to use the "number of corneal grafts performed in the United States" as the denominator. The EBAA Medical Advisory Board had endorsed this approach, because of potential underreporting of adverse reactions occurring internationally. EBAA data report a total number of 354,930 corneal grafts performed in the United States from 2007 to 2014. Table 1 illustrates the number of grafts increased incrementally each year, from a low of 39,391 in 2007 to a high of 48,229 in 2013.
With regards procedure type, the predominant corneal transplant performed in the United States was PK at 195,859 grafts (mean 24,482 per year), followed by EK at 164,563 grafts (mean 20,570 per year), and ALK at 7517 grafts (mean 940 per year). There was an incremental increase in EK procedures noted over this time period (Table 2 ).
Adverse Reactions
Of the 494 adverse reactions reported (Table 1) , PGF was the most common (65%) followed by endophthalmitis (20%), infectious keratitis (13%), donor-to-host transmission of systemic infection (0.6%), donor corneal dystrophy or degeneration (0.4%), donor corneal refractive surgery (0.4%), iritis (0.2%), and residual stromal edema (0.2%).
Primary Graft Failure Incidence
PGF was reported in 319 cases (mean 40 cases/year) for an incidence of 9 per 10,000 grafts performed in the United States ( Table 1) .
The procedure type predominantly associated with PGF was EK in 56% (n = 180) followed by PK in 42% (n = 135) and ALK in 1% (n = 3) of cases. Figure 1 illustrates the incidence data (per 10,000 grafts performed in the United States) relative to the procedure type. Although the incidence of PGF between PK (6.9 cases) and EK (11 cases) was noteworthy, the difference was not statistically significant (P = 0.098).
The mate cornea was transplanted in 281 of the 319 cases, with PGF occurring in 45 of the 281 (16%) recipient eyes. EK was the most common procedure type occurring in 27 (60%) of mated cases; tissue preparation was performed using the microkeratome by the eye bank in 25 cases and by the surgeon in 2 cases.
Donor Corneal Characteristics
The mean donor age was 54.5 years (range, 1 month to 86 years). The mean endothelial cell density was 2793 cells/ mm 2 (range, 1961-6000 cells/mm 2 ). The mean death to preservation was 10.7 hours (range, 1-25 hours), and the mean death to surgery was 6.8 days (range, 1-243 days). The tissue used 243 days postmortem was a scleral graft preserved in 100% ethyl alcohol.
The most common donor cause of death in patients with PGF was heart disease in 32% (n = 103), cancer in 24% (n = 77), other in 13% (n = 43), trauma in 12% (n = 39), respiratory disease in 8% (n = 26), stroke in 8% (n = 24), and toxic/accident in 2% (n = 7).
Post-Keratoplasty Endophthalmitis Incidence
Endophthalmitis was reported in 99 cases (mean 12 cases/year) for an incidence of 2.8 per 10,000 grafts performed in the United States ( Table 2 ). The trend showed an increase from a low of 5 cases in 2007 to a high of 26 in 2013 (P , 0.01). The relative number of fungal infections likewise shows an increasing trend from a low of 2 cases in 2007 to a high of 16 cases in 2013 (P , 0.05). Figure 2 similarly illustrates an increasing incidence from a low of 1.3 in 2007 to a peak of 5.4 in 2013.
The seasonal variation showed a higher proportion of fungal infection in springtime as compared with fall, summer, and winter (52% vs. 38%, 41%, and 42%, respectively). However, this was not statistically significant (P = 0.73).
The median time to onset of endophthalmitis after corneal transplant was 14 days (range, 1-221). The median time for bacterial infection (2.5 days) was significantly shorter (P , 0.05) than fungal infection (33 days).
The procedure type predominantly associated with endophthalmitis was EK in 61% (n = 60) of cases followed by PK in 37% (n = 37), KPro in 1% (n = 1), and scleral graft in 1% (n = 1) of cases. Figure 3 illustrates the incidence data (per 10,000 grafts performed in the United States) relative to the procedure type. Although the incidence of endophthalmitis between PK (1.8 cases) and EK (3.6 cases) was noteworthy, the difference was not statistically significant (P = 0.098).
The mate cornea was transplanted in 86 of the 99 cases, with infection developing in 21 of the 86 (24%) recipient eyes: endophthalmitis in 20 eyes and keratitis in 1 eye. The concordance between matching recipient and mate culture in the 16 cases that had both cultures performed was as follows: Candida species in 75% (n = 12), Enterococcus species in 13% (n = 2), and Clostridium perfringens in 13% (n = 2). Culture was not performed in 4 of the recipient mates. †Total ARs is inclusive of cases reported with PGF (n = 319), endophthalmitis and keratitis (n = 165), scleral graft infection (n = 1), donor corneal dystrophy or degeneration (n = 2), donor corneal refractive surgery (n = 2), donor-to-host transmission of systemic infection (n = 3), iritis (n = 1), and residual stromal edema posttransplant (n = 1). ‡Per 10,000 grafts. AR, adverse reaction. 
Isolates
The causative pathogen was isolated in 78% (n = 77) of cases, no growth was reported in 10% (n = 10), and culture was not performed in 10% (n = 10) of cases. Table 3 illustrates the spectrum and frequency of organisms isolated, of which Candida species was the most common pathogen affecting 65% (n = 53) of cases.
Post-Keratoplasty Infectious Keratitis Incidence
Infectious keratitis was reported in 66 cases (mean 8 cases/year) for an incidence of 1.8 per 10,000 grafts performed in the United States. Table 2 illustrates an increasing trend from a low of 3 cases in 2007 to a high of 19 cases in 2014. The number of fungal infections likewise shows an increasing trend from a low of 2 cases in 2007 to a high of 13 cases in 2014. Figure 2 illustrates an increasing incidence from a low of 0.7 in 2007 to a high of 3.9 in 2014.
The seasonal variation showed a higher proportion of fungal infection in wintertime as compared with spring, summer, and fall (69% vs. 50%, 37%, and 55%, respectively). However, this was not statistically significant (P = 0.30).
The median time to onset of infectious keratitis after corneal transplant was 29 days (1-216 days) for all 66 cases. Fungal infection keratitis (n = 34) had a significantly longer time (P , 0.05) to onset of 45 days (3-216 days) compared with bacterial keratitis (n = 5) of 6 days (1-125 days) and herpes simplex keratitis (n = 3) of 24 days (16-30 days).
The procedure type predominantly associated with infectious keratitis was EK in 67% (n = 44) followed by PK in 29% (n = 19), ALK in 3% (n = 2), and KPro in 2% (n = 1). Figure 4 illustrates the incidence data (per 10,000 grafts performed in the United States) relative to the procedure type. The incidence data should be interpreted in context of a low number of KPro and ALK procedures being performed, compared with EK and PK.
The mate cornea was transplanted in 62 of the 66 cases, with infection developing in 12 of the 62 (19%) recipient eyes: endophthalmitis in 1 eye and keratitis in 11 eyes. The concordance between matching recipient and mate culture in the 8 cases that had both cultures performed was 100% (n = 8) for Candida or yeast species. Culture was not performed in 3 of the recipient mates.
Donor Corneal Characteristics
The mean donor age was 51.4 years (range, 2-74 years), mean death to preservation was 10.1 hours (range, 1.7-22 hours), and the mean death to surgery was 5.1 days (range, 2-13 days).
The most common donor cause of death in patients with keratitis was heart disease in 42% (n = 27), other in 17% (n = 11), cancer in 15% (n = 10), trauma in 15% (n = 10), stroke in 5% (n = 3), respiratory disease in 3% (n = 2), and toxic/ accident in 3% (n = 2).
Isolates
The causative pathogen was isolated in 64% (n = 42), no growth reported in 12% (n = 8), and culture not performed in 23% (n = 15) of cases. Table 4 illustrates the spectrum and frequency of organisms isolated, of which Candida species was the most common pathogen, affecting 81% (n = 34) of cases. Notably, all cases of herpes simplex virus (HSV) keratitis (n = 3) were diagnosed clinically by characteristic examination findings and response to antiviral treatment. There was no serologic confirmation or a history of prior HSV infection noted.
OTHER ADVERSE REACTIONS

Donor-to-host transmission of systemic infection was reported in 3 cases; however, the final determination after investigation in conjunction with the Centers for Disease
Control and Prevention was that none of these systemic infections were definitively because of the donor tissue. In 2010, the 2 tissue recipient cases reported included 1 of Herpes simplex encephalitis in a patient who underwent ALK and 1 of HIV in a patient who underwent PK. In 2011 a case of sporadic CJD was reported in a 72-year-old patient that underwent EK.
Donor corneal dystrophy or degeneration was reported in 2 cases that developed keratoconus: (1) in 2007, a case of definite transmission of keratoconus after PK for prior graft failure, from a donor with a history of keratoconus; (2) in 2014, a case of possible transmission of keratoconus after ALK for keratoconus. Although recurrence of the original disease is a plausible explanation, transmission of disease was determined to be likely because of the early presentation and severe clinical course.
Donor corneal refractive surgery was reported in 2 cases in 2013. Both cases underwent successful PK, and the mate tissue was healthy. Scleral graft infection was associated with gram-positive bacilli in 1 case in 2013. Iritis was reported in a single case that underwent PK in 2012. The rim culture was negative, and the mate tissue developed endophthalmitis.
Residual stromal edema after keratoplasty, not consistent with PGF, was reported in a single case that underwent EK in 2014. The tissue was precut using a microkeratome at the eye bank.
DISCUSSION
The importance of reporting adverse reactions relates to improving our practice patterns, ensuring that the field of tissue transplantation learns from these cases, and to potentially change practices to prevent their recurrence. Identifying trends may illustrate public health concerns and may lead to policy changes. An example of this includes the increasing trend in the incidence of post-keratoplasty fungal infections observed in our report. Subsequent policy changes that may be considered in light of this trend may include the following: (1) to consider supplementing corneal tissue preservation medium with an antifungal agent and (2) to communicate with corneal transplant surgeons regarding the potential benefit of submitting donor rims for fungal culture at the time of surgery. Although there is inconsistent consensus regarding the clinical utility of a positive bacterial rim culture result and risk of bacterial endophthalmitis, 13, 14 it is recognized that there is higher correlation between postkeratoplasty fungal infection and positive rim culture result. 15, 16 Despite this, a 2013 EBAA survey reported that only 29% of respondents were performing routine donor rim cultures (Aldave, Anthony. The Utility of Donor Corneal Rim Cultures: A Report of the EBAA Medical Advisory Board Subcommittee on Fungal Infection Following Corneal Transplantation. EBAA/Cornea Society Educational Symposium, November 2015. Las Vegas, NV).
Primary Graft Failure
Published incidence data for post-keratoplasty PGF vary according to the procedure type. Large cohort studies and registry data report the incidence post-PK to range between 0% and 12%. [1] [2] [3] [4] The Cornea Donor Study, which evaluated the effect of donor age on the success of PK, reported a PGF incidence of 0.27% (n = 3) from their cohort of 1090 cases. 3 An epidemiologic study from the Veneto Eye Bank Foundation in Italy reported a PGF incidence of 5.6% (n = 6) from 998 grafts used for PK. 1 Studies using Australian graft registry data report the PGF incidence after PK to range between 0.6% and 0.85% (n = 36 of 6031 grafts and n = 41 of 4834 grafts, respectively). 2, 4 Comparatively, PGF incidence after PK in our study was significantly lower, at 0.069% (n = 135) of 195,859 grafts.
The incidence of PGF after Descemet stripping endothelial keratoplasty has been reported to range between 0% and 29% (mean 5%) in a 2009 report by the American Academy of Ophthalmology regarding EK safety and outcomes. 17 The data from this report were a synopsis of the peer-reviewed literature and included 34 relevant articles. Comparatively, PGF incidence post-EK in our study was lower, at 0.11% (n = 180) of 164,563 grafts.
There are few reports comparing the incidence of PGF post-PK versus post-EK. One such study including a large cohort of 20,431 tissues distributed from Eversight (formerly the Midwest Eye Banks) reported a PGF incidence of 0.17% (n = 23 of 13,597) after PK and 0.60% (n = 41 of 6834) after EK. 18 Data reported from the Singapore Corneal Transplant Study similarly showed a higher PGF rate of 1.5% after EK (n = 1 of 68 grafts) versus 0.5% after PK (n = 1 of 173 grafts). 19 Similarly, our study showed a higher PGF rate post-EK versus post-PK (0.11% vs. 0.069%).
The reason for a higher PGF incidence noted with EK compared with PK is likely multifactorial. There may be inconsistent understanding of the definition of PGF and overreporting as a result. Specifically, PGF is a graft that has not cleared 8 weeks after keratoplasty, is presumed to have occurred because of primary corneal endothelial failure, and is not iatrogenic because of excessive damage incurred during the surgical procedure. Learning curve and surgeon skill factors in to this, as EK has become more widely adopted. Overreporting occurs when these iatrogenic cases are included in the data. It is conceivable that our data from the OARSS report is more likely to have weeded out these iatrogenic cases because of the multiple checks in place to ensure accurate reporting. Specifically, tissue imputability is closely scrutinized by the distributing eye bank, the medical director, and the EBAA medical review subcommittee. This may explain our lower PGF incidence data compared with the published literature.
In addition, reporting is voluntary and at the discretion of the transplant surgeon. Medical standards require that the distributing eye bank send a post-keratoplasty outcome request to the surgeon, but do not necessarily require a documented response, which may lead to underreporting.
Endophthalmitis
The majority of publications reporting the incidence of postkeratoplasty endophthalmitis refer to PK, with less incidence data available relative to EK. The reported incidence of endophthalmitis, which has been generally derived from individual institutions, international registry data, and Medicare databases, ranges from 0.142% to 0.67%. [5] [6] [7] [8] [9] [10] EBAA data published by Hassan et al 8 reported 162 cases of endophthalmitis after PK from 1994 to 2003. The incidence was 0.047% (n = 162) of 340,174 grafts performed in the United States. In comparison, our study had a lower endophthalmitis incidence of 0.018% (n = 37) of 195,859 grafts for PK and 0.028% (n = 99) of 354,930 grafts for all corneal transplant types combined. Du et al 7 conducted a Medicare database review from 2006 to 2011 of postkeratoplasty endophthalmitis cases diagnosed within 6 weeks of surgery (based on International Classification of Diseases, 9th revision) and reported an incidence of 0.42% (n = 76) from 18,083 corneal transplants, in comparison with the incidence after cataract surgery of 0.127% (n = 2874) from 2,261,779 cases.
A study including a large cohort of 11,320 transplant recipients published using the UK transplant registry between 1999 and 2006 reported an endophthalmitis incidence of 0.67% (n = 76) after primary PK. 6 A retrospective review of endophthalmitis cases between 1990 and 2007 from the King Khaled Eye Specialist Hospital in Saudi Arabia reported an incidence of 0.61% (n = 46) of 7488 corneal transplants, including penetrating and lamellar keratoplasties. 5 A study from Emory University in Atlanta including 1010 consecutive penetrating keratoplasties reported an endophthalmitis incidence of 0.39% (n = 4). 9 Taban et al 10 reviewed published data between 1972 and 2002 of endophthalmitis cases after PK and noted an incidence of 0.382% from 90,549 grafts. They also observed a decreasing incidence of endophthalmitis cases after 1992, compared with 1991 and earlier. However, our report reveals an increasing trend of endophthalmitis cases reported over the past several years (Fig. 2) , seemingly because of increased fungal pathogens.
Fungal Infections
The reported incidence of fungal infection is approximately 0.033% to 0.16% after corneal transplant. 7, 9, 20 The incidence of fungal infection including keratitis and endophthalmitis after PK was reported to be 0.16% (n = 4) of 2466 grafts, from the New York Eye and Ear Infirmary. 20 Our study similarly shows low combined fungal infection incidence after keratoplasty at 0.023% (n = 83) of 354,930 grafts.
Review of the literature suggests that bacterial endophthalmitis after PK is more common than fungal etiology. The report by Hassan et al 8 In contrast, our study reveals a reversal of this trend, with a predominance of fungal infection in 65% (n = 53) versus bacterial infection in 35% (n = 29), of the 77 culturepositive cases. Of note, our endophthalmitis cases include those after both PK and EK.
Possible reasons for the relative increased incidence of fungal causative pathogens include the following: (1) To date, there is no routine use of an antifungal agent to supplement corneal storage medium in the United States. (2) A noncompetitive environment is created by increased broadspectrum antibiotic use killing off bacteria, thus allowing fungi to flourish. (3) The increased warming period time associated with preparing EK tissue in the eye bank has been shown to correlate with increased fungal organism proliferation (Tu, Elmer. The Effect of Repeated Warming Cycles of Corneal Storage Media on Fungal Infection Risk in Endothelial Keratoplasty. EBAA/Cornea Society Educational Symposium, November 2015. Las Vegas, NV). Conversely, the antibacterial activity of Optisol-GS is enhanced at room temperature, thus creating a noncompetitive environment allowing fungi to grow. 21 Reports suggest a high association between fungal infection and EK and tissue prepared in the eye bank, as compared with surgeon-prepared tissue. 15 Donor-to-host transmission of infection or malignancy is a rare but important consideration associated with corneal transplantation. 22 Possible underreporting may result from difficulty in confirming causative role of systemic transmission and the very long latency period of conditions, such as CJD and HIV. In our study, none of the 3 reported systemic infections were definitively confirmed to be because of the donor tissue. Maddox et al 23 reported the incidence of sporadic CJD cases unrelated to donor tissue, based on a review of 4 cases over a 16-year period, to occur in 1 case every 1.5 years.
Of note, only probable and definite graft-transmitted adverse reactions were considered reportable categories up until the end of 2013. The EBAA Medical Standard has since been modified so as to harmonize adverse reporting categories with the European SOHO V&S (Vigilance and Surveillance of Substances of Human Origin) categories. The current medical standard defines possible, likely/probable, and definite/certain as reportable adverse reaction categories. A limitation of this study is that donor factor analysis was limited because OARRS only contains donor characteristics data for cases with adverse reactions. Future study comparing unaffected and affected cases should examine whether any donor factors (eg, cause of death, donor on ventilator) are associated with these adverse reactions. 
